Business · 12/10/2011Updated: 10/17/2026 · 1 min read
National Institutes of Health to Grant Exclusive Patent License for Human Anti-Mesothelin Monoclonal Antibodies
The National Institutes of Health is considering granting an exclusive patent license to Sanomab, Ltd. for the development of human anti-mesothelin monoclonal antibodies for the treatment of human cancers, as outlined in several patent applications filed with the US Patent and Trademark Office and other regulatory agencies.